Unaudited interim results

Solvonis Therapeutics PLC

30 September 2026

 

30 September 2026

Solvonis Therapeutics PLC

Unaudited interim results for the six months to 30 June 2026

Solvonis Therapeutics Plc (the "Company" or "Solvonis"), a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system ("CNS") disorder presents its unaudited interim results for the six months to 30 June 2026.

Chairman's Statement

The first half of 2026 saw Solvonis advance its clinical and discovery programmes, strengthen its intellectual property portfolio and sharpen its strategy for delivering shareholder value.

SVN-001, our lead programme for severe Alcohol Use Disorder, remained central to that strategy. In April, the Board confirmed its intention to prioritise advancement through completion of Phase 3, reflecting our belief that successful results could create substantially greater value and strengthen our position in future strategic discussions. We retain flexibility over how best to realise that value.

In June, positive preclinical bridging data marked an important step forward for SVN-002, our esketamine oral thin-film programme for moderate-to-severe Alcohol Use Disorder in the United States. These results support the planned 505(b)(2) regulatory pathway and provide the basis for further FDA engagement ahead of a planned Phase 2b trial.

Our proprietary pipeline also progressed. We selected SVN-114 as the lead candidate for our PTSD programme, while two U.S. composition-of-matter patents covering distinct chemical series strengthened the programme's broader intellectual property estate. Positive preclinical findings supported SVN-015's expansion into depression, complementing its selection for U.S. National Institute on Drug Abuse-funded evaluation in stimulant use disorder.

Since the period end, we have announced a £1.3 million placing, including participation from a new UK institutional investor, and appointed Turner Pope as corporate broker. The funding is intended to support assessment of potential European sites for SVN-001's Phase 3 study, advancement of SVN-002 towards a U.S. IND submission and Phase 2b readiness, and continued development of SVN-015.

Further scientific progress followed. In August, NIDA selected SVN-015 for additional funded preclinical evaluation following encouraging initial cardiac ion-channel and off-target screening. In September, a European composition-of-matter patent allowance further strengthened the supporting chemistry estate around our PTSD programme.

Water Tower Research also initiated commissioned coverage in July, building on its appointment during the first half and supporting our efforts to broaden U.S. investor awareness.

Our priorities remain clear: advance SVN-001 towards its Phase 3 outcome, progress SVN-002 towards U.S. clinical development and build the value of our proprietary programmes through targeted investment. Disciplined capital allocation remains central to our approach.

On behalf of the Board, I thank our shareholders for their continued support and our team and research partners for their commitment.

Key Financial Indicators

·    Cash and cash equivalents at period end were £659,000 (H1 2025: £1,719,000)

·    Loss before taxation for the period was £1,437,000 (H1 2025: £1,621,000)

·    The Group held net assets at period-end of £4,810,000 (H1 2025: £6,935,000)

·    The Group held total assets at period-end of £6,427,000 (H1 2025: £9,545,000)

Risk factors

The principal risks and uncertainties for the remaining six months of the financial year remain the same as those contained within the annual report and accounts as at 31 December 2025.

Statement of directors' responsibilities

The directors confirm that these condensed interim financial statements have been prepared in accordance with UK adopted International Accounting Standard 34, 'Interim Financial Reporting' and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom's Financial Conduct Authority and that the interim management report includes a fair review of the information required by DTR 4.2.7 and DTR 4.2.8, namely:

·    an indication of important events that have occurred during the first six months and their impact on the condensed set of financial statements, and a description of the principal risks and uncertainties for the remaining six months of the financial year; and

·    material related-party transactions in the first six months and any material changes in the related-party transactions described in the last annual report.

On behalf of the Board,

Dennis Purcell

Non-Executive Chairman

Solvonis Therapeutics Plc

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
[e-mail]

Turner Pope Investments (TPI) Limited
Corporate Broker
Andrew Thacker / Guy McDougall
[phone]

SOLVONIS THERAPEUTICS PLC - CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE 6 MONTH PERIOD ENDING 30 JUNE 2026

	Note	Unaudited Six months to 30 Jun 2026 £'000	Unaudited Six months to 30 Jun 2025 £'000
Continuing operations
Administrative expenses	4	(1,437)	(1,617)
Operating loss		(1,437)	(1,617)
Finance costs		-	(4)
Loss before taxation		(1,437)	(1,621)
Taxation		-	-
Loss after taxation for the period from continuing operations		(1,437)	(1,621)
Other comprehensive income
Foreign currency translation		30	(115)
Other comprehensive income (net of tax) for the year		(1,407)	(1,736)
Total comprehensive loss for the period attributable to equity holders of the parent		(1,407)	(1,736)
Loss per share (p)	5	(0.021)	(0.055)

The notes form an integral part of the Condensed Consolidated Interim Financial Statements

SOLVONIS THERAPEUTICS PLC - CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2026

	Note	Unaudited 30 Jun 2026 £'000	Unaudited 30 Jun 2025 £'000	Audited 31 Dec 2025 £'000
Non-current assets
Intangible assets	6	5,667	7,710	5,667
Total non-current assets		5,667	7,710	5,667
Current assets
Cash and cash equivalents		659	1,719	1,720
Trade and other receivables		101	115	198
Total current assets		760	1,834	1,918
TOTAL ASSETS		6,427	9,545	7,585
Non-current liabilities
Loan note		72	77	75
Other non-current liabilities		901	981	839
Total non-current liabilities		973	1,058	914
Current liabilities
Trade and other payables		644	1,551	480
Total current liabilities		644	1,551	480
Total liabilities		1,617	2,609	1,394
NET ASSETS		4,810	6,935	6,191
Equity
Share capital	8	6,743	5,846	6,743
Share premium	8	10,870	9,143	10,870
Share based payment reserve	9	2,569	1,737	2,543
Capital reduction reserve		2,500	2,500	2,500
Foreign exchange reserve		(140)	(115)	(170)
Retained earnings		(17,732)	(12,176)	(16,295)
TOTAL EQUITY		4,810	6,935	6,191

The notes form an integral part of the Condensed Consolidated Interim Financial Statements.

The Condensed Consolidated Interim Financial Statements were approved and authorised by the Board of Directors on 30 September 2026.

Dennis Purcell - Chairman

SOLVONIS THERAPEUTICS PLC - CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

AS AT 30 JUNE 2026

	Share capital	Share premium	Capital Reduction Reserve	Share based payments reserve	Foreign exchange reserve	Retained earnings	Total equity
	£'000	£'000	£'000	£'000	£'000	£'000	£'000
Balance at 31 December 2024	2,233	7,362	2,500	1,544	-	(10,555)	3,084
Loss for period	-	-	-	-	-	(1,621)	(1,621)
Other comprehensive income	-	-	-	-	(115)	-	(115)
Total comprehensive loss for period	-	-	-	-	(115)	(1,621)	(1,736)
Transactions with owners in own capacity
Shares issued in period	1,538	462	-	-	-	-	2,000
Shares issued on acquisition of subsidiary	2,075	1,348	-	-	-	-	3,423
Share issue costs	-	(29)	-	-	-	-	(29)
Release of SBP charges	-	-	-	193	-	-	193
Transactions with owners in own capacity	3,613	1,781	-	193	-	-	5,587
Balance at 30 June 2025	5,846	9,143	2,500	1,737	(115)	(12,176)	6,935
Loss for period	-	-	-	-	-	(4,119)	(4,119)
Other comprehensive income	-	-	-	-	(55)	-	(55)
Total comprehensive loss for period	-	-	-	-	(55)	(4,119)	(4,174)
Transactions with owners in own capacity
Ordinary Shares issued in the period	877	1,737	-	-	-	-	2,614
Exercise of warrants	20	-	-	-	-	-	20
Share issue costs	-	(10)	-	-	-	-	(10)
Employee options issued	-	-	-	366	-	-	366
Warrants issued on Acquisition	-	-	-	440	-	-	440
Transactions with owners in own capacity	897	1,727	-	806	-	-	3,430
Balance at 31 December 2025	6,743	10,870	2,500	2,543	(170)	(16,295)	6,191
Loss for period	-	-	-	-	-	(1,437)	(1,437)
Other comprehensive income	-	-	-	-	30	-	30
Total comprehensive loss for period	-	-	-	-	30	(1,437)	(1,407)
Transactions with owners in own capacity
Employee options charge released	-	-	-	26	-	-	26
Transactions with owners in own capacity	-	-	-	26	-	-	26
Balance at 30 June 2026	6,743	10,870	2,500	2,569	(140)	(17,732)	4,810

SOLVONIS THERAPEUTICS PLC - CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

CONSOLIDATED STATEMENT OF CASHFLOWS

FOR 6 MONTH PERIOD ENDING 30 JUNE 2026

	Unaudited Six months to 30 June 2026 £'000	Unaudited Six months to 30 Jun 2025 £'000
Cash flow from operating activities
Loss before tax	(1,437)	(1,621)
Adjustments for:
Finance expenses	-	4
Share based payments	26	193
Foreign exchange movements	2	(96)
Changes in working capital:
Decrease in trade and other receivables	97	5
Increase in trade and other payables	245	501
Net cash outflow from operating activities	(1,067)	(1,014)
Cash flow from investing activities
Cash acquired on acquisition of subsidiary	-	8
Net cash inflow from investing activities	-	8
Cash flows from financing activities
Proceeds from issue of shares	-	2,000
Share Issue Costs	-	(29)
Net cash inflow from financing activities	-	1,971
Net (decrease)/increase in cash and cash equivalents	(1,067)	965
Cash and cash equivalents at beginning of period	1,720	757
Foreign exchange impact on cash	6	(3)
Cash and cash equivalents at the end of the period	659	1,719

SOLVONIS THERAPEUTICS PLC - CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE 6 MONTH PERIOD ENDING 30 JUNE 2026

1.         GENERAL INFORMATION

Solvonis Therapeutics Plc ("the Company" or "Solvonis") was incorporated in England and Wales as a limited company on 18 May 2017 under the name Graft Polymer (UK) Plc and was re-registered as a public limited company on 1 July 2021. On 10 January 2025 the Company changed its name to Solvonis Therapeutics Plc. The Company is domiciled in England and Wales with its registered office at Eccleston Yards, 25 Eccleston Place, London, SW1W 9NF. The Company's registered number is 10776788.

The principal activities of the Company and all of its subsidiaries collectively referred to as "the Group" are the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders.

The condensed consolidated interim financial statements ("interim financial statements") were approved for issue by the Board of Directors on 30 September 2026.

2.         ACCOUNTING POLICIES

IAS 8 requires that management shall use its judgement in developing and applying accounting policies that result in information which is relevant to the economic decision-making needs of users, that are reliable, free from bias, prudent, complete and represent faithfully the financial position, financial performance and cash flows of the entity.

3.         BASIS OF PREPARATION

The interim financial statements of Solvonis Therapeutics Plc for the six-month period ended 30 June 2026 have been prepared in accordance with Accounting Standard IAS 34 Interim Financial Reporting.

The interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 31 December 2025, which was prepared in accordance with UK adopted International Accounting Standards (IFRS) and the Companies Act 2006, and any public announcements made by Solvonis during the interim reporting period and since.

These interim financial statements do not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The Group's statutory financial statements for the year ended 31 December 2025 prepared under IFRS have been filed with the Registrar of Companies at Companies House and the same policies adopted in these accounts have been applied in the preparation of these interim financial statements. The auditor's report on those financial statements was unqualified and did not contain a statement under Section 498(2) of the Companies Act 2006.

The functional currency for each entity in the Group is determined as the currency of the primary economic environment in which it operates.  The presentational currency of the Group is Pounds Sterling as this is the currency in which equity fundraising has been facilitated. The functional and presentational currency of the Company is Pounds Sterling. The subsidiary functional currencies are the Euro, the Canadian Dollar and the United States Dollar depending on which jurisdiction the respective companies are domiciled in.

The interim financial statements have been rounded to the nearest £'000.

The interim financial statements have not been audited.

The business is not considered to be seasonal in nature.

3.1       GOING CONCERN

These interim financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the normal course of business. 

As disclosed in the interim financial statements, the consolidated entity incurred a net loss before taxation for the period ended 30 June 2026 from continuing operations of approximately £1,437,000 (30 June 2025: approximately £1,621,000) and had net cash outflows of approximately £1,067,000 for the period ended 30 June 2026 (30 June 2025: inflows of approximately £966,000). As at period end, the consolidated entity had net current assets of approximately £116,000 (30 June 2025: net current assets of approximately £234,000) and had cash and cash equivalents equal to approximately £659,000 (30 June 2025: approximately £1,719,000). 

The Directors note that the auditors included a material uncertainty related to going concern for the year ending 31 December 2025 however post period end the Company completed a fundraise, raising £1.3m for the Company allowing it sufficient runway to continuing advancing its primary programs and meet its other financial obligations. As a result, the Directors have assessed that the Group now has sufficient working capital to execute its operations over the next 12 months. Accordingly, the Directors believe that the Group will be able to continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the interim financial statements. 

3.2       PRINCIPAL RISK AND UNCERTAINTIES

There has been no material change in the principal risks and uncertainties of the Group since the publication of the Group's last audited annual report for the year ending 31 December 2025 and the Directors do not expect them to change over the remaining 6 months to the next reporting date.

3.3       CRITICAL ACCOUNTING ESTIMATES

The preparation of these interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses, and disclosure of contingent assets and liabilities at the end of the reporting period.

In preparing these interim financial statements, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were similar to those that applied to the financial statements for the period ended 31 December 2025 (unless specifically detailed below) with the nature and amounts of such estimates have not changed significantly during the interim period. New critical accounting estimates considered by management for the interim period were:

Recoverability of investments in subsidiary & intangible assets

During the prior year the Company acquired the Awakn Life Sciences Group ("Awakn") and has subsequently recorded an intangible asset in relation to the acquisition. This asset was assessed for impairment as part of the year end impairment review. There has been no material change in the recoverability or underlying value of the asset since the year end consequently the Directors do not consider the asset to be impaired. The recent fundraise supports the underlying value and gives the Directors confidence however the assets will be regularly monitored for signs of impairment.

Share based payments - (Note 9)

The Group issues options and warrants to its employees, directors, investors and advisors. These are valued in accordance with IFRS 2 "Share-based payments". In calculating the related charge on issuing shares and warrants the Group will use a variety of estimates and judgements in respect of inputs used including share price volatility, risk free rate, and expected life. Changes to these inputs may impact the related charge. In the period the Group did not perform any new valuations but released expenses over the vesting period to the statement of other comprehensive income from valuations in prior periods.

4.         ADMINISTRATIVE EXPENSES

		Unaudited Period to 30 Jun 2026 £'000	Unaudited Period to 30 Jun 2025 £'000
Research & Development		426	26
Directors' fees		181	85
Professional fees		134	586
Consultants		83	663
Administrative Expenses		613	257
		1,437	1,617

5.         EARNINGS PER SHARE

The calculation of the basic and diluted earnings per share is calculated by dividing the profit or loss for the period by the weighted average number of ordinary shares in issue during the period.

	Unaudited Period to 30 Jun 2026	Unaudited Period to 30 Jun 2025
Loss for the period from continuing operations - £ '000s	(1,437)	(1,621)
Weighted number of ordinary shares in issue	6,806,403,493	3,010,558,337
Loss per share from continuing operations - p	(0.021)	(0.055)

Share options and warrants could potentially dilute basic earnings per share in the future. These were not included in the calculation and no diluted earnings per share presented as the Group is loss making and additional equity instruments are anti-dilutive for the periods presented.

6.         INTANGIBLE ASSETS

	Note		£'000
Cost and carrying value - 30 June 2025			7,710
Impairment - FVLCD			(175)
Impairment			(2,088)
Year-end audited adjustment			223
Foreign exchange movement			(3)
Cost and carrying value - 31 December 2025			5,667
Movement			-
Cost and carrying value - 30 June 2026			5,667

7.         INVESTMENTS

Company subsidiary undertakings

The Group owned interests in the following subsidiary undertakings, which are included in the financial statements:

Name	Business Activity	Country of Incorporation	Registered Address	Percentage Holding
Awakn Life Sciences Corp	Holding company	Canada	217 Queen St W, Suite 301, Toronto, ON M5V 0R2, Canada	100%
Awakn Life Sciences Inc	Holding company	Canada	217 Queen St W, Suite 301, Toronto, ON M5V 0R2, Canada	100%
Solvonis Therapeutics UK R&D Limited	Holding company	UK	Eccleston Yards. 25 Eccleston Place, London, SW1W 9NF	100%
Solvonis Therapeutics US R&D Limited	Holding company	US	838 Walker Rd, Suite 21-2, 19904	100%
1233705. Ltd	Dormant company	Canada	217 Queen St W, Suite 301, Toronto, ON M5V 0R2, Canada	100%
Solvonis Therapeutics Ireland Holdings Limited	Holding company	Ireland	90 Leinster Rd. Dublin, Ireland D06F3P4	100%
Solvonis Therapeutics Ireland R&D Ltd	Holding company	Ireland	90 Leinster Rd. Dublin, Ireland D06F3P4	100%
Awakn LS Partnerships Limited	Holding company	Ireland	90 Leinster Rd. Dublin, Ireland D06F3P4	100%

8.         SHARE CAPITAL

	Number of shares	Share     capital	Share premium	Total
Ordinary shares		£'000	£'000	£'000
Opening balance - 30 June 2025	5,908,770,690	5,846	9,143	14,989
Fundraising shares	712,121,210	712	1,538	2,250
Shares in lieu of fees	165,511,593	166	199	365
Exercise of Warrants	20,000,000	20	-	20
Share issue costs	-	-	(39)	(39)
Opening balance - 31 December 2025	6,806,403,493	6,743	10,870	17,613
	-	-	-	-
Closing balance - 30 June 2026	6,806,403,493	6,743	10,870	17,613

Issued and fully paid ordinary shares with a nominal value of £0.001 (2025: £0.001)

9.         SHARE BASED PAYMENT RESERVE

	Group £'000
At 30 June 2025	1,737
Issue of LTIP Options	537
Issue of warrants to Awakn shareholders	247
Release of prior year LTIP charge	22
At 31 December 2025	2,543
Employee options released1	26
At 30 June 2026	2,569

¹Charge relates to options issued in prior period with a vesting period spanning multiple periods. Consequently, the share-based payment charge is released to the profit and loss over the course of the vesting period.

Warrants

	As at 30 June 2026
	Weighted average exercise price	Number of warrants
Brought forward at 1 January 2026	0.1p	274,500,000
	1p	703,465,432
		977,965,432
Granted in period	-	-
Outstanding at 30 June 2026	0.77p	977,965,432
Exercisable at 30 June 2026	0.77p	977,965,432

Options

	As at 30 June 2026
	Weighted average exercise price	Number of options
Brought forward at 1 January 2026	0.1p	235,000,000
	0.34p	42,000,000
	0.16p	21,000,000
		298,000,000
Granted in period	-	-
Outstanding at 30 June 2026	0.138p	298,000,000
Exercisable at 30 June 2026	0.138p	237,666,667

10.       ASSET ACQUISITION

Acquisition of awakn life sciences group

On 27 May 2025, Solvonis acquired 100% of the common shares of Awakn Life Sciences Corp ("Awakn"), restricted share units of Awakn and deferred share units of Awakn pursuant to a plan of arrangement under section 288 of the Business Corporations Act (British Columbia).

In accounting for the acquisition, the directors must ascertain whether Awakn satisfies the criteria to be classified as a business. Under IFRS 3, a business must have three elements: inputs, processes and outputs to constitute a business combination.

At acquisition Awakn and all of its subsidiaries ("collectively referred to as the "Group") were largely inactive with only a small number of underlying assets. Whilst entities within the Group did hold patents any exploitation of these patents had been halted and there the Group did not satisfy the 3 elements above to be considered a business.

Therefore, the Directors conclusion was that the transactions were asset acquisitions and not business combinations.

The details of Solvonis' acquisition of the Awakn Group are as follows:

	Unaudited Period to 30 Jun 2026	Unaudited Period to 30 Jun 2025	Audited Period to 31 Dec 2025
Net assets acquired	£'000	£'000	£'000
Trade and other receivables	65	56	65
Cash and cash equivalents	8	8	8
Other current assets	(73)	14	(73)
Other current liabilities	(1,680)	(1,965)	(1,680)
Total	(1,680)	(1,887)	(1,680)

Total purchase price
Amount settled in shares	3,422	3,422	3,422
Value of warrants issued as part of acquisition	440	-	440
Write off loans	300	300	300
Total	4,162	3,722	4,162

Total intangible asset acquired

5,842

5,609

5,842

11.       RELATED PARTY TRANSACTIONS

Payments to Directors

In the period Directors accrued fees as per below which were outstanding at period end:

	Fees accrued in the period (£)	Outstanding Fees as at 30.06.26 (£)
Anthony Tennyson	125,000	29,917
Renata Crome	12,000	2,000
Dennis Purcell	20,000	3,333
Nicholas Nelson	12,000	2,000
Paul Carter	12,000	2,000

12.       EVENTS SUBSEQUENT TO PERIOD END

Equity fundraise and placing

On 25^th August 2026, the Company completed an equity fundraise, raising £1.3 million through the issue of 1,083,333,333 new ordinary shares at a placing price of £0.0012. Alongside the placement, 10,000,000 shares were also issued in lieu of fees. In connection with the placement the Company also granted warrants over a total of 133,333,333 new ordinary shares at a price of £0.0012, exercisable at any time five years from Admission with an exercise price equal to the placing price.

 

END